Biphasic cell pleural mesothelioma is an asbestos-related cancer that forms on the pleura — the membranes lining the chest cavity and surrounding the lungs. Life expectancy for a biphasic mesothelioma diagnosis depends on which cell type is most prevalent in the tumor.
Biphasic is the second-most common cell type for mesothelioma.
About 20 to 35 percent of all malignant mesothelioma cases are biphasic. It is less common than the epithelial cell type and more common than sarcomatoid type.
Biphasic cell mesothelioma is found more often in the pleural form of the disease than in other forms of mesothelioma.
Symptoms of biphasic pleural mesothelioma can resemble signs of a less serious condition.
A 2019 Expert Review of Respiratory Medicine article describes signs of the disease as nonspecific. They can include cough, shortness of breath, chest wall pain, fatigue and weight loss.
If you have a history of asbestos exposure and experience any symptoms of pleural mesothelioma, discuss this with your doctor.
Letting your doctor know about your past work around asbestos will help minimize the risk of misdiagnosis.
Determining the mesothelioma cell type is part of the diagnostic process for pleural mesothelioma.
Sometimes the two cell types making up a biphasic tumor grow together. In many cases, they appear in separate areas of a single tumor. A single biopsy (tumor tissue sample) may only contain one of the two types of mesothelioma cells making up the tumor, leading to misdiagnosis.
For this reason, multiple biopsies from all identified pleural mesothelioma tumors is the best way to obtain an accurate diagnosis of the biphasic cell type.
The ASCO 2018 pleural mesothelioma treatment guidelines recommend suspected mesothelioma tumors be tested using immunohistochemistry.
This type of tissue testing helps identify the presence and absence of cell markers to confirm the mesothelioma diagnosis and rule out other diseases. These tests also add information to help determine whether the cells are epithelial, sarcomatoid or biphasic.
The 2015 World Health Organization Classification of Tumors of the Pleura recommend a minimum 10 percent epithelial and 10 percent sarcomatoid cells be present in a tumor in order to diagnose biphasic mesothelioma.
However, the 2017 Update of the Consensus Statement from the International Mesothelioma Interest Group indicates these designations may not be useful for determining disease prognosis and treatment choices.
Mesothelioma treatment is generally chosen based on the stage and location of the tumor rather than the type of cells that are present.
This means biphasic pleural mesothelioma patients may still be eligible for the common treatments for mesothelioma, such as:
Because mesothelioma is rare, it’s important for patients to find a mesothelioma specialist to guide their care, determine their cell type and create a treatment plan.
You can ask for a second opinion from a mesothelioma specialist — a normal part of the cancer care process — if you feel you need more information to fully understand your medical situation and available treatment options.
4 Cited Article Sources
Sponsored by The Peterson Firm, 1050 30th Street NW, Washington, DC 20007 © 2019 PleuralMesothelioma.com